An interleukin-6 receptor polymorphism is associated with opisthorchiasis-linked cholangiocarcinoma risk in Thailand

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 13, 2014, Pages 5443-5447

  Prayong, Pokpong ^a   Mairiang, Eimorn ^a   Pairojkul, Chawalit ^a   Chamgramol, Yaovalux ^a   Mairiang, Pisaln ^a   Bhudisawasdi, Vajarabhongsa ^a,b   Sripa, Banchob ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Cholangiocarcinoma; Interleukin 6 polymorphism; Opisthorchiasis; PCR RFLP

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ALLELE; BILE DUCT CARCINOMA; CASE CONTROL STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; OPISTHORCHIASIS; RISK; RISK FACTOR; THAILAND;

ALLELES; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; OPISTHORCHIASIS; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN-6; RISK; RISK FACTORS; THAILAND;

EID: 84905381782     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.13.5443     Document Type: Article

References (40)

1. Blechacz B, Gores GJ (2008). Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology, 48, 308-21.
2. Bouvard V, Baan R, Straif K, et al (2009). A review of human carcinogens-Part B: biological agents. Lancet Oncol, 10, 321-2.
3. Bustamante M, Nogues X, Mellibovsky L, et al (2007). Polymorphisms in the interleukin-6 receptor gene are associated with bone mineral density and body mass index in Spanish postmenopausal women. Eur J Endocrinol, 157, 677-84.
4. Dosquet C, Schaetz A, Faucher C, et al (1994), Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer, 30, 162-7.
5. Esteve E, Villuendas G, Mallolas J, et al (2006). Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin Endocrinol, 65, 88-91.
6. Galicia JC, Tai H, Komatsu Y, et al (2006). Interleukin-6 receptor gene polymorphisms and periodontitis in a non-smoking Japanese population. J Clin Periodontol, 33, 704-9.
7. Galicia JC, Tai H, Komatsu Y, et al (2004). Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun, 5, 513-6.
8. Goydos JS, Brumfield AM, Frezza E, et al (1998). Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg, 227, 398-404.
9. Gu F, Qureshi AA, Niu T, et al (2008). Interleukin and interleukin receptor gene polymorphisms and susceptibility to melanoma. Melanoma Res, 18, 330-5.
10. Heinrich PC, Behrmann I, Haan S, et al (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J, 374, 1-20.
11. Heinrich PC, Behrmann I, Muller-Newen G, et al (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J, 334, 297-314.
12. Huai JP, Ding J, Ye XH, et al (2014). Inflammatory bowel disease and risk of cholangiocarcinoma: evidence from a meta-analysis of population-based studies. Asian Pac J Cancer Prev, 15, 3477-82.
13. Hull J, Campino S, Rowlands K, et al (2007). Identification of common genetic variation that modulates alternative splicing. PLoS Genet, 3, 99.
14. IARC (1994). Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis). IARC Monogr Eval Carcinog Risks Hum, 61, 121-75.
15. Jiang CQ, Lam TH, Liu B, et al (2010). Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD. Obesity, 18, 1969-74.
16. Kim LH, Lee HS, Kim YJ, et al (2003). Identification of novel SNPs in the interleukin 6 receptor gene (IL6R). Hum Mutat, 21, 450-1.
17. Lamas JR, Rodriguez-Rodriguez L, Varade J, et al (2010). Influence of IL6R rs8192284 polymorphism status in disease activity in rheumatoid arthritis. J Rheumatol, 37, 1579-81.
18. Mairiang E, Laha T, Bethony JM, et al (2012). Ultrasonography assessment of hepatobiliary abnormalities in 3359 subjects with Opisthorchis viverrini infection in endemic areas of Thailand. Parasitol Int, 61, 208-11.
19. Malhi H, Gores GJ (2006). Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol, 45, 856-67.
20. Manwong M, Songserm N, Promthet S, et al (2013). Risk factors for cholangiocarcinoma in the lower part of Northeast Thailand: a hospital-based case-control study. Asian Pac J Cancer Prev, 14, 5953-6.
21. Marinou I, Walters K, Winfield J, et al (2010). A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility. Ann Rheum Dis, 69, 1191-4.
22. Matsumoto K, Onoyama T, Kawata S, et al (2014). Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma. Intern Med, 53, 651-4.
23. Mullberg J, Oberthur W, Lottspeich F, et al (1994). The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol, 152, 4958-68.
24. Mullberg J, Schooltink H, Stoyan T, et al (1993). The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol, 23, 473-80.
25. Ninlawan K, O'Hara SP, Splinter PL, et al (2010). Opisthorchis viverrini excretory/secretory products induce Toll-like receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyte. Parasitol Int, 59, 616-21.
26. Okada S, Okusaka T, Ishii H, et al (1998). Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol, 28, 12-5.
27. Park J, Tadlock L, Gores GJ, et al (1999). Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology, 30, 1128-33.
28. Qi L, Rifai N, Hu FB (2007). Interleukin-6 receptor gene variations, plasma interleukin-6 levels, and type 2 diabetes in U.S. Women. Diabetes, 56, 3075-81.
29. Reich D, Patterson N, Ramesh V, et al (2007). Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet, 80, 716-26.
30. Shin HR, Oh JK, Masuyer E, et al (2010). Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma-focus on East and South-Eastern Asia. Asian Pac J Cancer Prev, 11, 1159-66.
31. Sripa B, Brindley PJ, Mulvenna J, et al (2012a). The tumorigenic liver fluke Opisthorchis viverrini-multiple pathways to cancer. Trends Parasitol, 28, 395-407.
32. Sripa B, Kaewkes S, Sithithaworn P, et al (2007). Liver fluke induces cholangiocarcinoma. PLoS Med, 4, e201.
33. Sripa B, Mairiang E, Thinkhamrop B, et al (2009). Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology, 50, 1273-81.
34. Sripa B, Pairojkul C (2008). Cholangiocarcinoma: lessons from Thailand. Cur Opin Gastroenterol, 24, 349-56.
35. Sripa B, Thinkhamrop B, Mairiang E, et al (2012b). Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. PLoS Negl Trop Dis, 6, e1654.
36. Subrungruanga I, Thawornkunob C, Chawalitchewinkoon-Petmitrc P, et al (2013). Gene expression profiling of intrahepatic cholangiocarcinoma. Asian Pac J Cancer Prev, 14, 557-63.
37. Wang H, Zhang Z, Chu W, et al (2005). Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. J Clin Endocrinol Metab, 90, 1123-9.
38. Wise C, Pilanthananond M, Perry BF, et al (2008). Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol, 14, 2986-9.
39. Wu CW, Wang SR, Chao MF, et al (1996). Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol, 91, 1417-22.
40. Wu Q, He XD, Yu L, et al (2012). The metabolic syndrome and risk factors for biliary tract cancer: a case-control study in China. Asian Pac J Cancer Prev, 13, 1963-9.